Completed PHASE2 INTERVENTIONAL 3-arm NCT02511353

Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL)

Sponsor: Centers for Disease Control and Prevention

Conditions Malaria

Interventions dihydroartemisinin-piperaquine ivermectin placebo

Updated 7 times since 2017 Last updated: Aug 21, 2018 Started: Jul 31, 2015 Primary completion: Jul 31, 2016 Completion: Jul 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02511353, this PHASE2 trial focuses on Malaria and remains completed. Sponsored by Centers for Disease Control and Prevention, it has been updated 7 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

May 2018 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — May 2018 [monthly]

Completed PHASE2

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centers for Disease Control and Prevention
Kenya Medical Research Institute
Liverpool School of Tropical Medicine

Data source: Liverpool School of Tropical Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kisumu, Kenya